Forecasting the future burden of primary total shoulder replacement in Australia.


Journal

Osteoarthritis and cartilage
ISSN: 1522-9653
Titre abrégé: Osteoarthritis Cartilage
Pays: England
ID NLM: 9305697

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 21 02 2023
revised: 13 08 2023
accepted: 31 08 2023
medline: 27 11 2023
pubmed: 12 9 2023
entrez: 11 9 2023
Statut: ppublish

Résumé

To forecast the number of primary total shoulder replacements (TSR) in Australia to the year 2035, and associated costs. De-identified TSR data for 2009-2019 were obtained from the Australian Orthopaedic Association National Joint Replacement Registry. Population data, including population projections to 2035, were obtained from the Australian Bureau of Statistics. Three forecasting scenarios were used: constant TSR rates from 2019 onwards (Scenario 1, conservative); continued growth in TSR rates using negative binomial regression (Scenario 2, exponential); and continued growth using negative binomial regression with monotone B-splines (Scenario 3, moderate). Healthcare costs were estimated using TSR projections and average procedure costs, inflated to 2035 Australian dollars. The use of TSR increased by 242% in Australia from 2009 to 2019 (from 1983 to 6789 procedures for people ≥40 years). Under Scenario 1, the incidence of TSR is conservatively projected to rise to 9676 procedures by 2035 (43% increase from 2019), at a cost of $AUD 312.6 million to the health system. Under Scenario 2, TSR incidence would increase to 45,295 procedures by 2035 (567% increase), costing $AUD 1.46 billion. Under Scenario 3, 28,257 TSR procedures are forecast in 2035 (316% increase) at a cost of $913 million. Recent growth in TSR likely relates to prosthesis improvements, greater surgeon proficiency, and expanded clinical indications. Under moderate and exponential scenarios that consider rising TSR rates and population projections, Australia would face three- to five-fold growth in procedures by 2035. This would have profound implications for the healthcare budget, clinical workforce, and infrastructure.

Identifiants

pubmed: 37696387
pii: S1063-4584(23)00912-3
doi: 10.1016/j.joca.2023.08.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1636-1643

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Richard Page has received institutional education support for a Clinical Fellow (De Puy-Synthes).

Auteurs

Connor Fisher (C)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: cfis0005@student.monash.edu.

Sze-Ee Soh (SE)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; School of Primary and Allied Health Care, Monash University, Melbourne, Australia. Electronic address: sze-ee.soh@monash.edu.

Richard S Page (RS)

Barwon Centre for Orthopaedic Research and Education (B-CORE), Barwon Health and St John of God Hospital, Deakin University, Geelong, Australia; School of Medicine, Deakin University, Geelong, Australia; Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, Australia. Electronic address: richardpage@geelongortho.com.au.

Richard de Steiger (R)

Epworth HealthCare, Melbourne, Australia; Department of Surgery, The University of Melbourne, Melbourne, Australia. Electronic address: Richard.Desteiger@epworth.org.au.

Alana R Cuthbert (AR)

South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia. Electronic address: Alana.Cuthbert@sahmri.com.

Ilana N Ackerman (IN)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: ilana.ackerman@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH